High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
- 10 February 2010
- journal article
- case report
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 99 (2), 283-286
- https://doi.org/10.1007/s11060-010-0128-6
Abstract
Leptomeningeal metastases (LM) occur in 5–10% of patients with solid tumors and are associated with a dismal prognosis. We describe LM from lung adenocarcinoma harboring a mutation in the epidermal growth factor receptor (EGFR) gene that confers sensitivity to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) erlotinib and gefitinib. The CSF concentration of EGFR-TKIs achieved by standard daily dosing may be insufficient for therapeutic effect. However, intermittent (pulsatile) high dose administration (1000–1500 mg/week) achieves a higher CSF concentration than standard dosing, and successfully controlled LM in this patient.Keywords
This publication has 9 references indexed in Scilit:
- Carcinomatous Meningitis in Non–Small-Cell Lung Cancer: Response to High-Dose ErlotinibJournal of Clinical Oncology, 2009
- Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to ApoptosisCancer Cell, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose GefitinibJournal of Clinical Oncology, 2006
- A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancerCancer, 2006
- Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Clinical Cancer Research, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 2001